Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE: Trastuzumab
INDICATION: breast and stomach cancer
DATE: 26/07/2018
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
